Skip to main content
. 2023 Nov 20;9:e46474. doi: 10.2196/46474

Table 1.

Patient and tumor characteristics for cohort II (n=18,633).


All patients Node negative (n=14,829) Node positive (n=3804)
Age (years), median (range) 65 (22-95) 65 (22-95) 63 (23-94)
Menopausal status, n (%)

Premenopausal 3336 (19) 2515 (18.04) 821 (22.9)

Postmenopausal 14,224 (81) 11,457 (81.96) 2767 (77.12)

Missinga 1073 (5.76) 857 (5.8) 216 (5.7)
Mode of detection, n (%)

Mammographic screening 10,816 (58.17) 8992 (60.78) 1824 (48.01)

Symptomatic presentation 7777 (41.83) 5802 (39.22) 1975 (51.99)

Missing 40 (0) 35 (0) 5 (0)
Tumor size (mm), median (range) 15 (1-50) 14 (1-50) 19 (1-50)
Multifocality, n (%)

Absent 15,537 (83.54) 12,730 (85.98) 2807 (74)

Present 3061 (16.46) 2075 (14.02) 986 (26)

Missing 35 (0) 24 (0) 11 (0)
Histological type, n (%)

No special type 14,322 (76.86) 11,325 (76.37) 2997 (78.79)

Lobular 2387 (12.81) 1862 (12.56) 525 (13.8)

Other invasive, including mixed types 1924 (10.33) 1642 (11.07) 282 (7.4)
Nottingham histological grade, n (%)

1 4112 (22.32) 3600 (24.57) 512 (13.6)

2 9672 (52.49) 7595 (51.83) 2077 (55.03)

3 4643 (25.2) 3458 (23.6) 1185 (31.4)

Missing 206 (1.1) 176 (1.2) 30 (1)
Estrogen receptor status, n (%)

Negative (<1%) 1490 (8.32) 1199 (8.41) 291 (7.9)

Positive (≥1%) 16,423 (91.68) 13,053 (91.59) 3370 (92.05)

Missing 720 (3.9) 577 (3.9) 143 (3.8)
Progesterone receptor status, n (%)

Negative (<1%) 2672 (15.14) 2182 (15.56) 490 (13.5)

Positive (≥1%) 14,973 (84.86) 11,839 (84.44) 3134 (86.48)

Missing 988 (5.3) 808 (5.4) 180 (4.7)
Human epidermal growth factor receptor 2 status, n (%)

Negative 16,288 (88.67) 12,989 (88.87) 3299 (87.88)

Positive 2082 (11.33) 1627 (11.13) 455 (12.1)

Missing 263 (1.4) 213 (1.4) 50 (1)
Ki67 (%)

Values, median (range) 20 (0-100) 20 (0-100) 24 (1-100)

Missing, n (%) 133 (0.7) 123 (0.8) 10 (0)

aThe number of missing values is shown for noncomplete case variables.